SEER:NASDAQSeer, Inc. Analysis
Data as of 2026-08-02 - not real-time
$2.22
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Seer, Inc. trades at $2.22, comfortably above its 20‑day SMA (2.12) and the 50‑day SMA (1.90) but still below the 200‑day SMA (1.91), suggesting short‑term momentum without a clear long‑term trend. The RSI of 63 shows modest buying pressure, while the MACD histogram has turned negative, flagging bearish momentum. Volatility is extreme at ~99% over 30 days and beta sits above 1.5, indicating the stock moves sharply with the market. Fundamentals are weak – negative earnings, operating loss of ~‑6%, and a forward PE of –2.27 – yet the price‑to‑book of 0.51 and cash‑to‑market‑cap ratio (>1.3) imply a discount relative to net assets. The most material catalyst is the unsolicited acquisition proposal from CEO Omid Farokhzad at $2.45 per share plus contingent value rights, which could provide a modest premium if approved.
Given the high technical volatility, a cash‑rich balance sheet, and the pending shareholder vote on board nominations, the near‑term outlook hinges on whether the proposal gains traction. Absent a confirmed deal, the stock remains a high‑risk, value‑oriented play with limited upside beyond the proposed $2.45 price.
Given the high technical volatility, a cash‑rich balance sheet, and the pending shareholder vote on board nominations, the near‑term outlook hinges on whether the proposal gains traction. Absent a confirmed deal, the stock remains a high‑risk, value‑oriented play with limited upside beyond the proposed $2.45 price.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 6/10
Key Factors
- Unsolicited acquisition proposal offering a $2.45 per share premium
- Technical support near $1.82 and price above short‑term moving averages
- Strong cash position relative to market cap
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Uncertainty around shareholder approval and board composition
- Continued negative operating cash flow and earnings
- High volatility and beta suggesting price swings
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Fundamental deficits (negative margins, high debt‑to‑equity)
- Biotech sector's regulatory and execution risk
- Potential for value realization only if acquisition closes or profitability improves
Key Metrics & Analysis
Financial Health
Revenue Growth-33.60%
P/E Ratio-2.3
ROE-25.52%
ROA-15.04%
Debt/Equity9.54
P/B Ratio0.5
Op. Cash Flow$-48466000
Free Cash Flow$-31675124
Industry P/E29.2
Technical Analysis
TrendNeutral
RSI63.0
Support$1.82
Resistance$2.34
MA 20$2.12
MA 50$1.90
MA 200$1.91
MACDBearish
VolumeDecreasing
Fear & Greed Index92.88
Valuation
Target Price$4.00
Upside/Downside80.18%
GradeUndervalued
TypeValue
Risk Assessment
Beta1.04
Volatility99.17%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.